Purpose of the development: A pharmaceutical composition for the treatment of osteoporosis, as well as diseases associated with bone loss.

Recommended application field: Orthopedic and trauma hospitals.

Technical characteristic: The pharmaceutical composition may be formulated as solid unit dosage forms for oral administration (capsules, tablets, pastes, bulk powder), or liquid formulation (emulsion, suspension), dry or lyophilized form.

Advantages over analogues: The pharmaceutical composition: - increases the level of mineral components in the serum and bone; - normalizes the activity of the total alkaline phosphatase; - a positive effect on the structural and functional state of the bone tissue.

The development stage readiness: Ready for application

Description of the development:
()
The pharmaceutical composition has a positive effect in the treatment of bone tissue pathologies due to its ability to form a bond with the crystal surface of hydroxyapatite and inhibit bone resorption by acting on osteoblast activity, especially in combination with regulators of structural and functional state of the bone tissue - calcium and vitamin D3.

Information about newness of the development:
there are Ukrainian patents -- 1 items

corresponds technical description
Ready for implementation

Possibility of transfer abroad:
Combinated reduction to industrial level

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua